Follow
Novartis’ Sandoz
Novartis AG is a Swiss-American multinational pharmaceutical corporation based in Basel, Switzerland and Cambridge, Massachusetts, United States (World Research). It is one of the largest pharmaceutical companies in the world.
Novartis makes the drugs clozapine (Clozaril), diclofenac (Voltaren; sold to GlaxoSmithKline in 2015 deal), carbamazepine (Tegretol), valsartan (Diovan), imatinib mesylate (Gleevec/Gleevec), cyclosporine (Neofaralim) (Neofremarozole). , methylphenidate (Ritalin; discontinued 2020), terbinafine (Lamisil), deferasirox (XZ), and others.
In March 1996, the companies Ciba-Geigy and Sandoz merged to form Novartis; The pharmaceutical and agrochemical divisions of both companies form Novartis as an independent entity. Other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis merged its generic drug businesses into a single subsidiary and renamed it Sandoz. Novartis expanded from its agrochemical and genetically modified crops business with the spinout of Syngenta in 2000 in partnership with AstraZeneca, which also spun off its agrochemical business.
Novartis is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA), the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), and the Pharmaceutical Research and Manufacturers of America (PhRMA).
Novartis AG is a publicly traded Swiss holding company operating through the Novartis Group. Novartis AG directly or indirectly owns all companies worldwide that operate as affiliates of the Novartis Group.
Novartis’ business is divided into three operating segments: Innovative Medicines, Sandoz (Generic) and Alcon (Eye Care). In April 2019, Novartis spun off Alcon as a separate company. In August 2022, Novartis announced plans to spin off Sandoz as part of a restructuring. The Innovative Medicines segment consists of two business units: Novartis Pharmaceuticals and Novartis Oncology: Novartis operates through 150 direct subsidiaries, each of which falls under one of the divisions and which Novartis classifies as fulfilling one or more of the following functions: Holding/Finance, Sales, production, and research
Novartis AG held a 33.3 percent stake in Roche until 2022, but it did not exercise control over Roche. Novartis has two significant license agreements with Genentech, a Roche subsidiary. A contract for Lucentis; The other is for Xolair.:239
In 2014, Novartis established a center in Hyderabad, India, to offshore several of its research and development, clinical development, medical writing and administrative functions. The center supports the operations of drug majors in pharmaceuticals (Novartis), eye care (Alcon) and generic drug segments (Sandoz).
